Bioactivity | Subasumstat (TAK-981) is a first in class and selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities[1][2]. | ||||||||||||
Target | SUMOylation. | ||||||||||||
Invitro | Subasumstat (TAK-981) is able to increase the production of type 1 IFN, thereby increasing type 1 IFN-mediated signaling, activating innate effector cells and enhancing the antitumor innate immune responses[1]. | ||||||||||||
In Vivo | A single sub-cutaneous injection of Subasumstat (TAK-981) in naive Balb/c mice at the brachial lymph nodes induces activation of DCs[2]. | ||||||||||||
Name | Subasumstat | ||||||||||||
CAS | 1858276-04-6 | ||||||||||||
Formula | C25H28ClN5O5S2 | ||||||||||||
Molar Mass | 578.10 | ||||||||||||
Appearance | Solid | ||||||||||||
Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
Storage |
|
||||||||||||
Reference | [1]. Sumoylation inhibitor TAK-981. [2]. TAK-981. |